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Abstract
Purpose
To investigate the association between clinical PET (positron emission tomography) type
and oncologic outcome in resectable pancreatic cancer.
Methods
Between January 2008 and October 2012, patients who underwent potentially curative
resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment
were retrospectively investigated. Clinical PET type was defined as follows: pancreatic can-
cer with similar 18FDG uptake to renal calyx was determined as kidney-type (K-type), and
relatively lower 18FDG uptake than that of renal calyx was regarded as Non-K type.
Results
A total of 53 patients were enrolled. After agreement-based reclassification, agreement
based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type
(aNon K-type) was found in 19 patients (35.8%). There was a significant difference between
aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19–9
(P = 0.007), maximum standard uptake value (SUVmax,P<0.001), metabolic tumor volume
(MTV2.5, P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n =
31) showed a significantly shorter disease-free time compared with Non-K type (n = 16)
(10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior disease-
free survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012).
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Conclusions
Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can
be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.
Introduction
18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography/computed tomography
(PET/CT) scan is the functional imaging technology used to detect tumors with a high meta-
bolic rate. It can also provide quantification of metabolic activity such as maximum standard
uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for
estimating tumor biology and clinical translation [1,2].
In general, overexpression of glucose transporters and hexokinases has been reported in
many cancer cells[3]. 18F-FDG is taken up by up-regulated surface glucose transporters and is
phosphorylated by hexokinases. Glucose-6-phosphatase dephosphorylates glucose (FDG) to
participate in the normal metabolic process. However, cancer cells have low expression of glu-
cose-6-phosphatase compared to many normal tissues, and this can lead to an accumulation
of 18F-FDG-P in tumor cells[4–6]. The 18F-FDG-PET scan is currently being used for cancer
diagnosis[7], staging[8], identifying hidden metastasis, and assessment of treatment responses
[9] in clinical oncology.
There have been several studies showing the oncologic significance of 18F-FDG-PET scans
in predicting prognosis in pancreatic cancer [10–12]. Specifically, Dholakia et al[13] recently
reported that MTV and TLG are significant prognostic factors of overall survival in patients
with locally advanced pancreatic cancer. Epelbaum et al. [14] assessed the role of a quantitative
dynamic PET model in pancreatic cancer and concluded that global 18F-FDG influx was the
most important parameter to predict overall survival. Yamamoto et al. [15] evaluated the clini-
cal usefulness of 18F-FDG-PET scans as a prognostic marker in resected pancreatic cancer and
found that an SUVmax greater than 6.0 was a significant predictor of early postoperative recur-
rence and poor survival in resected pancreatic cancer.
Although there are important studies suggesting potential associations between PET-based
parameters and oncologic outcomes, the calculation and official documentation of individual
PET-based parameters might not be routine in clinical practice because these processes usually
require time- and labor-consuming processes for the radiologists. In addition, these parame-
ters are somewhat subjective and prone to observer variability [16].
Interestingly, some studies have shown a potential relationship between image-based inter-
pretation of tumors and oncologic outcome in treating malignant disease [17–21]. In this
study, we analyzed the clinical feasibility of quick “qualitative” assessment of FDG-uptake in
resectable pancreatic cancer by surgeons. We tried to correlate this clinical PET type with clini-
copathological characteristic and oncologic outcome in resected pancreatic cancer. The goal of
this study was to propose a qualitatively assessed clinical PET-type method that can be an alter-
native prognostic marker in resectable pancreatic cancer.
Materials and methods
Patient selection and clinicopathologic characteristics
We retrospectively reviewed medical records of patients who underwent potentially curative
resection for resectable pancreatic ductal adenocarcinoma. Only patients who underwent
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surgical resection with preoperative 18F-FDG PET/CT as part of a staging work-up between
January 2008 and October 2012 were included. Unresectable locally advanced pancreatic
cancer and metastatic pancreatic cancer were excluded. In addition, those who received preop-
erative neoadjuvant treatment for borderline or locally advanced pancreatic cancer on preop-
erative imaging modalities were excluded due to potential impact of neoadjuvant treatment
[22]. The study was reviewed and approved by the Institutional Review Board of Yonsei Uni-
versity College of Medicine.
The variables of gender, age, tumor location, operation type, tumor size, preoperative
serum CA 19–9 (actual CA 19–9), adjusted CA 19–9 (calculated as actual CA 19–9 divided
by initial serum bilirubin), grade (differentiation), pathologic tumor (pT) stage, presence of
lymph node metastasis (pN), lymph node ratio (total number of metastatic lymph nodes
divided by total number of retrieved lymph nodes), retrieved number of LNs, number of
metastastic LNs, microscopic perineural invasion, lymphovascular invasion, recurrence, and
time to recurrence were retrospectively reviewed. Maximum standard uptake value (SUVmax),
metabolic tumor volume (MTV2.5), and total lesion glycolysis (TLG) were measured by two
nuclear medicine physicians as described previously [10,23]. Each tumor was examined with a
spherical-shaped volume of interest (VOI). SUVmax of the VOI was calculated as (decay-cor-
rected activity/tissue volume)/(injected dose/body weight). MTV2.5 was defined as total tumor
volume with an SUV of 2.5 or greater. TLG was calculated as (mean SUV) x (MTV2.5). In
order to assess the possible influence of renal function on FDG uptake, estimated glomerular
filtration rate (eGFR) and serum creatinine (Cr) levels were also reviewed.
Determining clinical PET type
Perceived signal intensity of 18FDG in the renal calyceal system was used as a reference to cate-
gorize clinical PET type. Pancreatic cancer with similar 18FDG uptake to that of the renal calyx
was determined as K-type (Fig 1a), and pancreatic cancer with relatively lower 18FDG uptake
than that of renal calyx was regarded as Non-K-type (Fig 1b). Three surgeons (Kang CM,
Hwang HK, Lee JH) were asked to categorize the patients according to this defining system
Fig 1. Determining clinical PET type based on perceived FDG-uptake intensity in the renal calyx. (a) K-type, the perceived signal
intensity of FDG-uptake in pancreatic head cancer (thick empty white arrow) is similar to that of the renal calyx(thin white arrow) (b) Non-K-
type, the perceived signal intensity of FDG-uptake in pancreatic head cancer (thick empty white arrow) is lower than that of the renal calyx
(thin white arrow).
doi:10.1371/journal.pone.0172606.g001
Clinical PET type for pancreatic cancer
PLOS ONE | DOI:10.1371/journal.pone.0172606 February 24, 2017 3 / 15
for clinical PET type. During the process of individual classification, the surgeons were not
allowed to communicate regarding their interim results. However, the respectively determined
clinical PET types were re-categorized as aK-type and aNon-K-type based on surgeon agree-
ment. Agreement-based reclassification of clinical PET type follows the agreed upon classifica-
tion of two surgeons. For example, if two surgeons determined a sample to be K-type and one
surgeon concluded Non-K-type, the agreement-based reclassification of clinical PET type
would be aK-type.
Statistical analysis
Continuous variables were described as mean ± standard deviation, and categorical variables
were described as frequency (%). Student’s t-test was used for these determinations. To esti-
mate inter-observer discrepancy, average agreement and Cohen’s Kappa values were analyzed,
and results were defined as follows: poor < 0.2, fair 0.21–0.4, moderate 0.41–0.6, substantial
0.61–0.8, and excellent 0.81–1[24]. Survival curves were estimated using the Kaplan-Meier
method to calculate cumulative disease-free survival. Statistical analyses were performed using
SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). P-values<0.05 were considered statisti-
cally significant.
Results
Patient demographics and defining clinical PET type in resectable
pancreatic cancer
A total of 53 patients were enrolled for this study (Fig 2). The clinicopathological characteris-
tics are summarized in Table 1. The mean disease-free survival was 20.8 months [95% CI:
15.6–26.1], and mean disease-specific survival was 30.5 months [95% CI: 24.3–36.7]. With
regard to clinical PET type, 31 patients (58.5%) were found to have K-type, and 16 patients
(31.2%) were Non-K-type. The other six patients (11.3%) had cancer whose type was unable to
be agreed upon by all surgeons. In terms of renal function, all patients had normal serum Cr
levels. However, 26 patients (49%) had eGFR below 90 mL/min/1.73m2 with mild to moderate
decrease [25]. There was no significant correlation between eGFR and SUVmax in patient with
normal serum creatinine levels (r = -0.115, P = 0.441).
Correlations between clinicopathological characteristics and clinical PET
type in resectable pancreatic cancer
There were no significant differences between K-type and Non-K-type pancreatic cancer in
terms of clinicopathological characteristics such as tumor size, pT-stage, pN-stage, lymphovas-
cular invasion, perineural invasion, and tumor differentiation (P>0.05). However, SUVmax
(P<0.001), MTV2.5 (P<0.001) and TLG (P<0.001) were found to be statistically different
between K-type and Non-K-type pancreatic cancer as determined by individual surgeons. Spe-
cifically, the actual CA 19–9 level appeared to be higher in K-type pancreatic cancer, but the
difference was not significant (P>0.05). However, the adjusted CA 19–9 was significantly dif-
ferent between two surgeons, S2 (448.6 ± 62.2 vs. 98.6 ± 153.9, P = 0.006) and S3
(434.8 ± 656.9 vs. 104.9 ± 156.3, P = 0.008, Table 2).
Analysis of inter-surgeon agreement
Overall, the inter-surgeon agreement was greater than 91% with a pairwise Cohen’s kappa of
0.81 (Table 3). After agreement-based reclassification, aK-type was noted in 34 patients
(64.2%), and aNon-K-type pancreatic cancer was found in 19 patients (35.8%, Table 4). There
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were significant statistical differences between agreement-based aNon-K-type and aK-type in
adjusted CA 19–9 (102.8 ± 156.9 vs. 435.9 ± 656.3, P = 0.007), tumor size (2.0 ± 0.4 vs.
2.5 ± 0.7, P = 0.030), SUVmax (3.1 ± 0.7 vs. 6.2 ± 2.8, P<0.001), MTV2.5 (1.0 ± 1.4 vs. 5.9 ± 4.6,
P<0.001), and TLG (3.2 ± 4.1 vs. 23.8 ± 22.6, P<0.001).
Fig 2. Patient eligibility.
doi:10.1371/journal.pone.0172606.g002
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Oncologic outcome according to clinical PET type in resectable
pancreatic cancer
It was found that preoperatively determined clinical PET type could predict tumor recurrence
after radical pancreatectomy. There was a significant difference in disease-free survival
between individually determined K-type and Non-K-type resected pancreatic cancer (P<0.05,
Table 5).
When analyzing oncologic outcomes according to agreement of all three surgeons, K-type
(N = 31, mean disease-free survival, 10.8 months [95% CI: 8.3–13.3]) showed significant early
recurrence compared with Non-K-type pancreatic cancer (N = 16, mean disease-free survival,
24.1 months [95% CI: 24.4–54.8], P = 0.013). Disease-free survival of six patients with dis-
agreed clinical type of 18FDG uptake among the surgeons showed similar oncologic outcomes
to Non-K-type patients (P = 0.237).
Finally, according to agreement-based reclassification, aK-type showed inferior mean dis-
ease-free survival compared to aNon-K-type pancreatic cancer (11.9 months [95% CI: 9.0–
14.9] vs. 28.6 months [95% CI: 20.2–36.9], P = 0.012, Fig 3).
Oncologic impact of postoperative chemotherapy according to clinical
PET type in resectable pancreatic cancer
Postoperative chemotherapy was offered to all patients after curative resection. However, 13
patients (25%) were not able to receive postoperative chemotherapy. Among these patients, 5
Table 1. Clinicopathological characteristics of the patients.
Variables Frequency, Mean ± SD
Age (years) 63.1 ± 9.2
Gender (Female/Male) 24/29
Tumor Size, cm 2.3 ± 0.7
Location (Head/Body/Tail) 38/12/3
CA 19–9, U/mL 509.6 ± 1675.9
PD(PPPD)/DPS/TP 6(32)/12/3
Grade (W/M/P/U) 8/39/6
T stage (T1/T2/T3) 2/2/49
N stage (N0/N1) 24/29
Retrieved LNs 18.3 ± 7.7
Metastatic LNs 1.3 ± 2.2
LNR 0.08 ± 0.11
PNI (No/Yes) 14/39
LVI (No/Yes) 34/19
R0/R1/R2 53/0/0
SUVmax 5.3 ± 2.8
MTV2.5 3.9 ± 3.8
TLG 16.9 ± 20.9
eGFR 91.9 ± 18.9
Serum Cr 0.80 ± 0.20
PD, pancreaticoduodenectomy; PPPD, pylorus preserving pancreaticoduodenectomy; Grade (W/M/P/U),
well-, moderate-, poor-, un-differentiated; LNs, lymph nodes; LNR, lymph node ratio; PNI, perineural
invasion; LVI, lymphovascular invasion; SUVmax, maximum standard uptake value; MTV2.5, metabolic tumor
volume; TLG, total lesion glycolysis; eGFR, estimated glomerular filtration rate; Cr, creatinine
doi:10.1371/journal.pone.0172606.t001
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patients (38%) refused further treatment, 3 patients (24%) developed postoperative complica-
tions preventing postoperative chemotherapy in a timely manner, and remaining 5 patients
(38%) did not recover well-enough for further treatment. There was no significant oncologic
impact of postoperative chemotherapy on patients with aNon-K-type pancreatic cancer
(mean 26.9 months [95% CI: 12.7–41.1] vs. 21.9 months [16.6–27.3], P = 0.780). However,
postoperative chemotherapy played a very important role in patients with aK-type pancreatic
cancer. In patients with aK-type pancreatic cancer, disease-free survival improved with post-
operative chemotherapy (mean 5.6 months [95% CI: 3.6–7.6] vs. mean 12.8 months [95% CI:
9.7–16.0], P = 0.035), leading to comparable oncologic outcomes with aNon-K-type without
Table 2. Clinicopathological differences according to individual surgeons’ clinical type of FDG-uptake.
S1 S2 S3
K Non-K K Non-K K Non-K
(N = 34) (N = 19) (N = 33) (N = 20) (N = 34) (N = 19)
Age, years 62.4 ± 9.9 64.4 ± 7.6 62.5 ± 9.9 64.1 ± 7.9 62.4 ± 9.9 64.7 ± 7.8
Gender (Female/Male) 15/19 09/10 14/19 10/10 14/20 10/9
Tumor Size, cm 2.5 ± 0.7 2.3 ± 0.8 2.5 ± 0.7 2.2 ± 0.8 2.5 ± 0.7 2.2 ± 0.8
Location (Head/Body/Tail) 22/9/3 16/3/0 23/8/2 15/4/1 23/8/3 15/4/0
Actual CA 19–9, U/mL 670.8 ± 2077.9 221.1 ± 245.6 703.7 ± 2104.2 189.2 ± 237.2 677.1 ± 2075.6 209.9 ± 260.8
Adjusted CA 19–9, U/mL 390.8 ± 625.1 183.5 ± 379.4 448.6 ± 62.2 98.6 ± 153.9a 434.8 ± 656.9 104.9 ± 156.3b
Grade (W/M/P/U) 3/27/4 5/12/2 4/25/4 4/14/2 4/26/4 4/13/2
T stage (T1/T2/T3) 3/2/29 2/2/15 1/2/30 1/0/19 1/2/31 1/0/18
N stage (N0/N1) 15/19 9/10 14/19 10/10 14/10 10/9
Retrieved LNs 17.2 ± 6.9 20.3 ± 8.6 17.7 ± 7.9 19.4 ± 8.6 17.4 ± 7.1 20.0 ± 8.6
Metastatic LNs 1.3 ± 2.5 1.4 ± 1.6 1.3 ± 2.5 1.4 ± 1.6 1.3 ± 2.5 1.4 ± 1.6
LNR 0.08 ± 0.11 0.09 ± 0.11 0.07 ± 0.11 0.08 ± 0.11 0.07 ± 0.11 0.08 ± 0.11
PNI (No/Yes) 10/24 4/15 7/26 7/13 8/26 6/13
LVI (No/Yes) 22/12 12/7 22/11 12/8 22/12 12/7
R0/R1/R2 34/0/0 19/0/0 33/0/0 20/0/0 34/0/0 19/0/0
SUVmax 6.3 ± 2.9 3.2 ± 0.6c 6.3 ± 2.9 3.2 ± 0.6d 6.2 ± 2.9 3.1 ± 0.6e
MTV2.5 5.5 ± 3.7 0.8 ± 0.9c 5.3 ± 3.8 1.1 ± 1.6d 5.4 ± 3.7 0.7 ± 0.9e
TLG 23.9 ± 22.5 3.0 ± 3.7c 23.7 ± 22.9 4.4 ± 6.7d 23.8 ± 22.5 3.0 ± 4.1e
Serum Cr 0.79 ± 0.19 0.81 ± 0.22 0.79 ± 0.19 0.81 ± 0.21 0.80 ± 0.19 0.80 ± 0.21
eGFR 91.4 ± 17.8 92.7 ± 21.2 91.5 ± 17.9 92.5 ± 20.9 92.2 ± 18.3 91.2 ± 20.3
S1, surgeon1; S2, surgeon2; S3, surgeon3; Grade (W/M/P/U), well-, moderate-, poor-, un-differentiated; LNs, lymph nodes; LNR, lymph node ratio; PNI,
perineural invasion; LVI, lymphovascular invasion; SUVmax, maximum standard uptake value; MTV2.5, metabolic tumor volume; TLG, total lesion glycolysis;
eGFR, estimated glomerular filtration rate; Cr, creatinine.
a P = 0.006,
b P = 0.008,
c,d,e P<0.001
doi:10.1371/journal.pone.0172606.t002
Table 3. Inter-surgeon discrepancy.
S1 and S2 S2 and S3 S3 and S1 Average value
Pairwise percent agreement (%) 88.679 90.566 94.34 91.195
Pairwise Cohen’s Kappa 0.752 0.797 0.878 0.81
S1, surgeon1; S2, surgeon2; S3, surgeon3
doi:10.1371/journal.pone.0172606.t003
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postoperative chemotherapy (P = 0.262). Results of univariate and multivariate analysis of dis-
ease-free survival for aK-type have also revealed that postoperative chemotherapy is an inde-
pendent prognostic factor in recurrence (HR 0.290, 95% CI: 0.086–0984, P = 0.047, Table 6).
However, postoperative chemotherapy still could not improve disease-free survival to the
extent of aNon-K-type pancreatic cancer with postoperative chemotherapy (P = 0.043, Fig 4).
Discussion
18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography/computed tomography
(PET/CT) is an emerging radiologic technique to detect functional (metabolic and biologic)
properties of cancer [26,27]. 18F-FDG-PET/CT is a potential preoperative image modality
because tumor biology can be estimated using PET-based parameters even in preoperative
staging situations.
In this study, we defined a qualitatively assessed clinical PET type and correlated it with
oncologic outcome of resected pancreatic cancer. Pancreatic cancers with an available preop-
erative PET-scan could be divided into K-type and Non-K-type according to perceived signal
intensity of 18F-FDG uptake compared to that shown in the renal calyx. There are other poten-
tial candidates for a reference organ for determining the signal of 18FDG uptake such as brain
and myocardium. However, to compare the signal intensity of FDG uptake in a pancreatic
tumor, one would need to frequently move the axial section-field to the chest level or even the
brain area, which would be inconvenient during clinical assessment of metabolic properties in
pancreatic cancer. On the contrary, the renal calyx can be easily visualized due to its proximity
to the pancreas, allowing it to be easily used as a reference organ in determining clinical PET
type in resected pancreatic cancer (Fig 1). Perceived intensity of FDG uptake in renal calyx
may be different among patients. However, clinical PET typing is derived from comparison
of perceived intensity of renal calyx and pancreatic cancer within the patient. This can be
achieved easily in a single image with use of renal calyx as reference, which is in proximity to
pancreas.
Table 4. Agreement-based clinical PET type in six patients in whom not all three surgeons agreed on PET type.
Patient Number S1 S2 S3 Agreement-based decision1
1 K-type Non K-type Non K-type aNon-K-type
2 Non K-type Non K-type K-type aNon-K-type
3 Non K-type K-type K-type aK-type
4 Non K-type K-type K-type aK-type
5 K-type Non K-type Non K-type aNon-K-type
6 K-type K-type Non K-type aK-type
S1, surgeon1; S2, surgeon2; S3, surgeon3
1Agreement-based decision of clinical PET type follows the agreed upon classification of at least two surgeons
doi:10.1371/journal.pone.0172606.t004
Table 5. Disease-free survival according to clinical PET type determined by individual surgeons.
K-type Non-K-type P-value
S1 17.6 months [95% CI:11.2–23.9] 24.5 months [95% CI:17.7–31.4] 0.035
S2 11.4 months [95% CI: 8.6–14.3] 29.3 months [95% CI: 21.1–37.5] 0.003
S3 11.9 months [95% CI: 9.1–14.7] 29.6 months [95% CI: 20.9–38.2] 0.007
S1, surgeon1; S2, surgeon2; S3, surgeon3; CI, confidence interval
doi:10.1371/journal.pone.0172606.t005
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Table 6. Univariate and multivariate analysis of disease-free survival for aK-type.
Variables N = 34 (%) Univariate analysis Multivariate analysis
p-value p-value HR (95%CI)
Age > 65 years 15 (44) 0.309
Male gender 20 (59) 0.058
ASA score 0.591
1 11 (32)
2 20 (59)
3 3 (9)
Tumor size 2.5cm 21 (62) 0.802
AJCC 7th stage 0.960
I/IIA 14 (41)
IIB 20 (59)
Postoperative chemotherapy 28 (82) 0.035 0.047 0.290 (0.086-0.984)
doi:10.1371/journal.pone.0172606.t006
Fig 3. Oncologic outcomes according to agreement-based reclassification of clinical PET type. aK-type, agreement-based K-type;
aNon K-type, agreement-based Non K-type.
doi:10.1371/journal.pone.0172606.g003
Clinical PET type for pancreatic cancer
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According to our results, the clinical PET type (K-type and Non-K-type) was found to suc-
cessfully discriminate disease-free survival in resected pancreatic cancer (P<0.05, Fig 3 and
Table 5). Results of our finding concur with previously reported association between SUVmax
greater than 6.0 with early postoperative recurrence following resection of pancreatic cancer
[15]. The present clinical PET type is based on surgeons’ perceptions of 18FDG uptake in the
tumor, with the renal calyx as the reference signal. Therefore, it is thought that clinical PET
type can be very subjective and so might not be reliable. However, unlike our expectations, the
agreement rate among three individual surgeons was estimated to be higher than 91.195%
with a pairwise Cohen’s Kappa value of 0.81, suggesting excellent inter-observer variability. In
previous reports, interobserver variation for SUVmean measurement has been noted up to 17%
[28] and interobserver agreement for SUVmax has been reported to be 91–93% [29]. This
means that application of clinical PET type can be reliably used as an alternative detectable
parameter to estimate tumor glucose metabolism and tumor biology in clinical setting.
Our data also showed a predictive value for tumor recurrence of clinical PET type, suggest-
ing it as a potential clinical biomarker to predict recurrence before surgical intervention,
especially when PET-based parameters are not documented in clinical practice. Biological
mechanism behind our results may be explained by the role of SUVmax in PET imaging. Kang
Fig 4. Oncologic role of postoperative chemotherapy according to clinical PET type in resectable pancreatic cancer. aK-type,
agreement-based K-type; aNon K-type, agreement-based Non K-type; CTx, postoperative chemotherapy.
doi:10.1371/journal.pone.0172606.g004
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et al. [30] reported that loss of SMAD4 is associated with poor oncologic outcome and this was
correlated with SUVmax to conclude that higher SUVmax was associated with loss of SMAD4.
Our results have shown that K-types have higher SUVmax (Table 2). This may explain poor dis-
ease-free survival of aK-type patients. Further research on role of PET imaging in prognosis of
pancreatic cancer is needed.
There are several other advantages of the current qualitative method of determination of
clinical PET type. First, the current system for determining clinical PET type is simple, easy,
reproducible, and practical. Without specialized effort and equipment to measure PET-based
parameters, surgeons or clinicians can estimate oncologic outcome during consultations with
patients who have had a preoperative PET scan on spot.
Second, in spite of surgeons’ subjective determination, PET-based parameters of SUVmax,
MTV, and TLG were significantly different between K-type and Non-K-type pancreatic cancer
(Table 4). In addition, when correlating clinical PET type and preoperative serum CA 19–9,
our data showed a higher level of preoperative actual CA 19–9, but the difference was not sta-
tistically significant. However, the adjusted CA 19–9 was found to be correlated with clinical
PET type for surgeons S2 and S3, suggesting that clinical PET type can be a useful preoperative
prognostic marker in resectable pancreatic cancer (Table 2). These observations should be
confirmed when analyzing data according to agreement-based clinical PET type.
Some studies have also suggested potential association between CA 19–9 and PET-based
parameters. Shi et al[31] showed that MTV and TLG were most strongly correlated with
serum CA 19–9 in patients with resected pancreatic cancer. Xu et al[12] also observed that
MTV and TLG were significantly associated with baseline serum CA 19–9, and MTV and TLG
showed strong consistency with baseline serum CA 19–9, leading to improved predictions of
oncologic outcome in resectable pancreatic cancer. In fact, we have already studied the onco-
logic significance of adjusted CA 19–9 in predicting tumor recurrence in resected pancreatic
cancer [32]. In the current data set, when setting the cut-off value of adjusted CA 19–9 to 80,
we were able to predict disease-free survival in resected pancreatic cancer (P = 0.044, data not
shown). Using a larger study volume, it will be necessary to validate this potential relationship
between clinical PET type and serum CA 19–9 in the near future.
Finally, it was shown that preoperatively determined clinical PET type, especially, K-type
pancreatic cancer, requires postoperative chemotherapy after radical pancreatectomy. Accord-
ing to our data, disease-free survival of aK-type pancreatic cancer is influenced by postopera-
tive adjuvant chemotherapy (Fig 3), suggesting that aK-type resectable pancreatic cancer can
benefit from postoperative chemotherapy. There are several studies evaluating the role of PET
scans in monitoring the clinical outcomes of patients with locally advanced pancreatic cancer
treated with neoadjuvant treatment[9,33,34]. However, there are very few studies that have
evaluated the potential role of preoperative PET scan in predicting the oncologic benefits of
postoperative adjuvant chemotherapy in resectable pancreatic cancer. Our results suggest that
preoperative PET scans can provide important data for decision for postoperative adjuvant
chemotherapy after radical pancreatectomy in resectable pancreatic cancer.
Since the goal of this study was to assess feasibility of qualitatively determined clinical PET
type by surgeons, patient population only included those under evaluation for operation.
Therefore, the results of current study have limitation in application to unresectable patients.
However, according to our clinical experiences of unresectable pancreatic cancer, most cases
seem to belong to K-type, suggesting aggressive tumor biology. Further studies based on a
larger population including unresectable cases are needed to confirm this observation.
This study is a retrospective study design harboring unavoidable selection bias because not
all patients underwent preoperative PET and some patients with neoadjuvant treatment were
excluded. In addition, PET parameters, especially SUVmax, can be influenced by tumor size
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[35,36]. Therefore, it might be difficult to discriminate between K-type and Non-K-type in
small pancreatic cancers, and our data supports this problem. This study showed that pancre-
atic cancer with disagreement in determination of clinical PET type was significantly smaller
than the agreed cases (1.8 ± 0.3 cm vs. 2.5 ± 0.7 cm, P = 0.002). When analyzing patients with a
radiologic tumor size greater than 2 cm, the average agreement rate increased to 93.3% with a
mean pairwise Cohen’s Kappa value of 0.822. Finally, we may not be able to apply clinical PET
type to all patients because there are also some clinical conditions that need to be considered,
such as impaired renal function[37] and dehydration. 18F-FDG is excreted through urine.
Therefore, renal function plays an important role in 18F-FDG metabolism. In patients with
renal impairment, insulin-mediated glucose metabolism is also reduced because of insulin
resistance [38]. This may influence FDG uptake in tissues. Accordingly, Torihara et al. [37]
have reported that patients with renal dysfunction showed higher physiological FDG uptake in
the soft tissue, spleen and blood pool. Despite the general assumption that impaired renal
function would influence the distribution and metabolism of 18F-FDG, recent report by Akers
et al.[8] has shown that impaired renal function does not influence clearance of background
activity of 18F-FDG PET imaging. Minamimoto et al. [38] have also reported that suspected
renal failure will not have a significant influence on assessment of PET imaging. In spite of
these findings, FDG uptake in renal calyx is decreased in patients with impaired renal function
because of reduced urine activity. Intense FDG uptake might not be seen even in the renal
calyx due to the amount of urinary flow at the moment the image was taken. In those cases, the
clinical PET type needs to be determined by anecdotal clinician’s memory of the usual inten-
sity of FDG uptake in the renal calyx. Our study results did not include patients with impaired
renal function. Limitations exist in determining clinical PET type for patients with abnormal
renal functions, however our results have shown that with normal serum Cr levels, mild to
moderate decrease in eGFR does not correlate with SUVmax. Nevertheless, clinical information
regarding renal function should be considered when applying clinical PET type.
In conclusion, the current results suggest the clinical feasibility of surgeons’ determined
clinical PET type as alternative prognostic marker in resectable pancreatic cancer. True reli-
ability and oncologic significance of clinical PET type need to be reassessed based on a pro-
spective cohort of a large number of patients with resectable pancreatic cancer.
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